Policy
UK Minister of State urged to champion psilocybin access in Parliament
A Parliamentary debate to discuss psilocybin access in the UK will be held on Thursday, 18 May.

Published
7 months agoon

The Royal College of Psychiatrists, Heroic Hearts and other leading mental health charities have written letters to the Veterans Minister and the Minister of State for Crime, Policing and Fire, urging them to champion access to psilocybin for mental health.
Following three years of campaigning from the Conservative Drug Policy Reform Group (CDPRGUK), Ministers will be joining to discuss access to psilocybin therapy in the UK.
Ahead of the debate, The Royal College of Psychiatrists and other leading mental health charities including Drug Science, Clusterbusters, the Campaign Against Living Miserably, Sane and Heroic Hearts Project UK, have written a letter to the Minister of State for Crime, Policing and Fire, MP Chris Philp.
The letter urges MP Philip to commission a high-priority ACMD review of psilocybin’s status as a Schedule 1 controlled substance under the Misuse of Drugs Regulations 2001.
Keith Abraham, CEO of Heroic Hearts UK, a non-profit organisation supporting veterans’ access to psychedelic therapies, has also written to the Minister of State (Minister for Veterans’ Affairs) Johnny Mercer.
Abraham is urging the Minister to “champion the issue within the Cabinet ahead of the Back Bench Business debate on the 18 May and demand that the Home Office commission an urgent review of the evidence of the harms and utility of psilocybin.”
Writing on behalf of veterans of Britain’s armed forces, Abraham penned: “I am heartened by your inclusion of mental health as a personal priority in your work for our community, and I write to you today because it’s highly probable we can do better for Veterans.
“Clinical studies into the effects of psilocybin on depression, combined with supportive psychotherapy, show very exciting evidence to suggest that even a single dose can relieve symptoms for long periods of time.”
Timmy Davis, CDPRG Psilocybin Rescheduling Project Manager, commented: “It has now been more than two years since the ACMD was asked to review barriers to research and after this review, a further commission would still be necessary to reschedule psilocybin.
“It is unethical to wait any longer. Psilocybin’s Schedule 1 designation is not morally, medically or economically appropriate. We hope that the ACMD can do the right thing by patients in the UK and show it is the independent and proactive body it is intended to be. Not least as it is chaired by a practicing psychiatrist.
“According to nationwide polling data, nearly 60% of the UK population supports changing the law to make it easier to research psilocybin.
“This proportion increased to 68% when respondents were told that similar reforms to enable research with psilocybin have already taken place in other jurisdictions around the world like Australia, Canada and the United States.”
Founder and Unremunerated Chair, CDPRG, MP Crispin Blunt, who will be one of the MPs leading the debate in Parliament, commented: “It is deeply frustrating that we have a medicine, psilocybin, that could transform mental health care for over a million people in the UK with severe depression, yet outdated Home Office restrictions are stifling UK research and blocking patient access.
“There is absolutely no evidence to justify this. The Home Office has admitted as much. I do not think people would accept this situation if it was a drug for cancer. Why do we treat psilocybin differently?
“18 people per day in the UK take their own lives from depression. A dozen more die of drug addiction. Millions suffer every day. We have a duty of care to these people. At present, we are failing in this duty, based on no evidence at all.”
To watch the debate on Thursday, 18 May visit: www.parliamentlive.tv/Commons
You may like
Psychedelic therapy programmes launch to address heartbreak, burnout and more
Psilocybin analogue shows positive results in Phase 2 depression study
Compass Pathways launches Phase 3 psilocybin trial in UK
PAREA’s psychedelic push: improving policy for mental health innovation in Europe
Oakland ballot seeks to legalise medical psychedelics
Enrollment completed in LSD trial for ADHD
Policy
Now is the time for psychedelic access, says campaigner

Published
1 week agoon
21st November 2023By
News Editor
Activists in Oakland recently filed a ballot put forward by Dave Hodges seeking to legalise safe and legal access to psychedelics for therapeutic uses.
In the face of critics, Hodges has said now is the time for safe access to psychedelics.
The Psychedelic Wellness & Healing Initiative would enable the sale, possession and use of psychedelics for therapeutic purposes if passed. Psychedelics that would be allowed under the ballot include Psilocybin, MDMA, DMT, and Mescaline.
If passed, the initiative would give doctors and mental health specialists the right to recommend psychedelics to ease the debilitating symptoms of a range of problems, including obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), depression, anxiety, addiction, suicidality and traumatic brain injury (TBI), among others.
Hodges has said: “Now is the time for safe, controlled medical access for patients in need. The way to solve the problem is not by continuing to ignore it.”
Hodges’ solution is to create a structure for use that includes proper dosages and access to experts who can help users benefit from appropriate treatment.
The updated initiative language emphasises safety, and gives doctors and mental health specialists the right to recommend psychedelics to ease the debilitating symptoms of a range of conditions.
Research by the University of Michigan and Columbia University shows non-LSD hallucinogenic use on the rise and Hodges has stated that increase means that the initiative providing guidelines for use is needed more than ever.
Hodges said he hopes Californians will read the initiative, share their thoughts about it over the holiday week and offer feedback via the initiative website, PW4CA.com, by 27 November, 2023, the deadline for modifications.
“Now is the time to provide medical and therapeutic access to psychedelics,” Hodges said. “The way to do this is through the initiative.”
Policy
Transform Drugs releases groundbreaking book: How to regulate psychedelics

Published
2 weeks agoon
15th November 2023
UK charity Transform Drug Policy Foundation has published a new book ‘How to Regulate Psychedelics: A Practical Guide’ that sets out how psychedelics can be legalised and regulated for non-medical adult use.
While an increasing amount of research is pointing to the potentially beneficial effects of psychedelic treatment on mental health conditions, many people across the globe are using psychedelics outside of the clinical setting.
The book includes a set of proposals for post-prohibition policies, covering psychedelics including psilocybin, LSD, DMT and Mescaline.
Previously, Transform’s guides on regulating stimulants and cannabis have been used to advise governments around the world on drug policy. This book seeks to inform the debates on psychedelic drug reforms taking place across the world.
Co-author and Public Affairs and Policy Manager at Transform Drug Policy Foundation, Ester Kincová, stated: “Despite psychedelic drugs being illegal, their non-medical use within society has been steadily increasing.
“Punitive enforcement has not decreased use or eliminated supply, but it has made use more unsafe.
“Legalising and regulating psychedelics is a pragmatic move to reduce harm. This is no longer a theoretical debate, states in the US are already recognising the need and making moves to regulate for non-medical adult use.”
Scientific Chair of Drug Science, Professor David Nutt, added: “Once again Transform have come up with a well thought out and practical plan for the regulation of another group of currently illegal drugs – in this case psychedelics.
“Their ideas would be both easy to implement and to engage with and will, if adopted, radically enhance the safe use of these remarkable agents.”
Proposals for regulation
The book includes a four-tiered regulation model “that attempts to manage the variety of psychedelic preparations and the different ways in which they are used”.
These include:
- Private use, home cultivation, foraging and not-for-profit sharing.
- Membership-based non-for-profit associations for plant-based products.
- Licensed production and retail adaptable to different products and environments
- Regulated commercial guided or supervised use
Additionally, a decriminalisation model is proposed which suggests that possession for personal use should no longer be an offence of any kind or be subject to any sanctions; Drugs for personal use should not be confiscated; cultivation of small amounts of plant-based drugs for personal use should be decriminalised, among other suggestions.
The book also includes topics such as embedding social justice, equity and human rights into policy design, how to think about psychedelics regulation, why regulate psychedelics and why now, and psychedelics and the UN drug treaties.
To read the book, please visit transformdrugs.org/.
Policy
Oakland ballot seeks to legalise medical psychedelics

Published
1 month agoon
30th October 2023By
News Editor
Activists in Oakland have filed a ballot that seeks to legalise safe and legal access to psychedelics for therapeutic uses.
The Psychedelic Wellness & Healing Initiative would enable the sale, possession and use of psychedelics for therapeutic purposes if passed. Psychedelics that would be allowed under the ballot include Psilocybin, MDMA, DMT, and Mescaline.
If passed, the initiative would give doctors and mental health specialists the right to recommend psychedelics to ease the debilitating symptoms of a range of problems, including obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), depression, anxiety, addiction, suicidality and traumatic brain injury (TBI), among others.
Additionally, it would create a statewide framework for regulating the possession, use, cultivation and production of substances for medical and therapeutic use.
The initiative has been introduced by proponent and founder of the Oakland-based Church of Ambrosia, Dave Hodges, to the California Attorney General’s office for the 2024 ballot, and will need 546,651 valid signatures to qualify.
The filing follows California Governor Gavin Newsom’s recent veto of Senate Bill 58, the bill that sought to decriminalise the use of certain psychedelic drugs.
Hodges emphasised that SB58 would have been a step forward, but that it had major flaws concerning its lack of provisions to ensure access, public safety and quality control. That veto, Hodges said, compelled him to move quickly on the initiative filing.
When the California Attorney General certifies the initiative for circulation, backers will have about four and a half months to gather the required signatures for ballot placement.
Signature collecting will begin in early December.
Recent Articles
- Psychedelic therapy programmes launch to address heartbreak, burnout and more
- Psilocybin analogue shows positive results in Phase 2 depression study
- Ketamine: understanding the K-Hole
- Mychedelica launches to revolutionise psychedelic medicine
- Clerkenwell Health calls for volunteers to support groundbreaking psychedelic research
- Short Wave Pharma: innovating eating disorder care with psychedelics
Trending
- Short Wave Pharma: innovating eating disorder care with psychedelics
- Clearmind Medicine announces receipt of Nasdaq delisting notice
- Paper explores extended difficulties following psychedelic trips
- Now is the time for psychedelic access, says campaigner
- Compass Pathways launches Phase 3 psilocybin trial in UK
Trending
- Opinion2 years ago
Clerkenwell Health is launching a free UK psychedelic therapist training programme
- Insight2 years ago
Mixing psychedelics with lithium poses significant risk of seizures
- Medicinal2 years ago
MDMA therapy for PTSD granted innovation passport by UK
- Research2 years ago
LSD trial for the treatment of adult ADHD initiated
- Markets & Industry11 months ago
Where can I find training for psychedelic therapy?
- Medicinal2 years ago
MDMA: the love drug?
- News2 years ago
Awakn’s second psychedelic therapy clinic to open in London
- Research2 years ago
London to host Europe’s first commercial psychedelic clinical trial facility